347 related articles for article (PubMed ID: 31900689)
1. Imaging of tumour response to immunotherapy.
Dromain C; Beigelman C; Pozzessere C; Duran R; Digklia A
Eur Radiol Exp; 2020 Jan; 4(1):2. PubMed ID: 31900689
[TBL] [Abstract][Full Text] [Related]
2. Tumor response assessment on imaging following immunotherapy.
Berz AM; Dromain C; Vietti-Violi N; Boughdad S; Duran R
Front Oncol; 2022; 12():982983. PubMed ID: 36387133
[TBL] [Abstract][Full Text] [Related]
3. Cancer Imaging in Immunotherapy.
Ayoub M; Eleneen Y; Colen RR
Adv Exp Med Biol; 2020; 1244():309-324. PubMed ID: 32301025
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy and the role of imaging.
Carter BW; Bhosale PR; Yang WT
Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
6. Elevated tumor markers for monitoring tumor response to immunotherapy.
Yang Y; Jiang X; Liu Y; Huang H; Xiong Y; Xiao H; Gong K; Li X; Kuang X; Yang X
EClinicalMedicine; 2022 Apr; 46():101381. PubMed ID: 35434583
[TBL] [Abstract][Full Text] [Related]
7. Cancer Imaging in Immunotherapy.
Ak M; Eleneen Y; Ayoub M; Colen RR
Adv Exp Med Biol; 2021; 1342():431-447. PubMed ID: 34972979
[TBL] [Abstract][Full Text] [Related]
8. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
Mushti SL; Mulkey F; Tang S; Singh H; Lemery SJ; Goldberg KB; Sridhara R; Keegan P; Kluetz PG; Pazdur R; Theoret MR; Beaver JA
Curr Oncol Rep; 2020 Aug; 22(11):116. PubMed ID: 32851542
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival.
Manitz J; D'Angelo SP; Apolo AB; Eggleton SP; Bajars M; Bohnsack O; Gulley JL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228264
[TBL] [Abstract][Full Text] [Related]
10. Cancer Imaging in Immunotherapy.
Eleneen Y; Colen RR
Adv Exp Med Biol; 2017; 995():141-153. PubMed ID: 28321816
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours].
Houdek Š; Büchler T; Kindlová E
Klin Onkol; 2017; 30(Supplementum3):32-39. PubMed ID: 29239190
[TBL] [Abstract][Full Text] [Related]
12. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
[TBL] [Abstract][Full Text] [Related]
13. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy.
Solinas C; Porcu M; Hlavata Z; De Silva P; Puzzoni M; Willard-Gallo K; Scartozzi M; Saba L
Crit Rev Oncol Hematol; 2017 Dec; 120():13-21. PubMed ID: 29198327
[TBL] [Abstract][Full Text] [Related]
14. Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From the
Sheikhbahaei S; Marcus CV; Sadaghiani MS; Rowe SP; Pomper MG; Solnes LB
AJR Am J Roentgenol; 2022 Jun; 218(6):940-952. PubMed ID: 34612682
[TBL] [Abstract][Full Text] [Related]
15. Challenges in assessing solid tumor responses to immunotherapy.
Chai LF; Prince E; Pillarisetty VG; Katz SC
Cancer Gene Ther; 2020 Aug; 27(7-8):528-538. PubMed ID: 31822814
[TBL] [Abstract][Full Text] [Related]
16. Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians.
Zhou H; Luo Q; Wu W; Li N; Yang C; Zou L
Front Immunol; 2023; 14():1088874. PubMed ID: 36936913
[TBL] [Abstract][Full Text] [Related]
17. Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events.
Elsherif SB; Anderson M; Chaudhry AA; Kumar SP; Gopireddy DR; Lall C; Bhosale PR
Eur J Radiol; 2022 Jan; 146():110062. PubMed ID: 34890935
[TBL] [Abstract][Full Text] [Related]
18. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
19. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
[TBL] [Abstract][Full Text] [Related]
20. [Tumour assessment criteria for immune checkpoint inhibitors].
Wasielewski E; Cortot AB
Rev Mal Respir; 2018 Oct; 35(8):828-845. PubMed ID: 30166076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
